Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate PF-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy

Trial Profile

A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate PF-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 5089771 (Primary) ; Pregabalin
  • Indications Diabetic neuropathies; Pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrial.gov record.
    • 20 Nov 2014 Planned End Date changed from 1 Apr 2017 to 1 May 2017 as reported by ClinicalTrial.gov record.
    • 20 Nov 2014 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017 as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top